{"disease":{"id":"long-term-maintenance-therapy-for-discrete-aldosterone-producing-adrenal-adenomas-in-non-surgical-candidates","name":"Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"aldactone","indication_name":"Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"aldactone","guideline_body":"FDA label","recommendation":"Spironolactone is indicated for long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery.","line_of_therapy":"maintenance","evidence_grade":"1B","guideline_year":null},{"drug_id":"aldactone","guideline_body":"FDA label","recommendation":"Spironolactone is indicated for long-term maintenance for patients with bilateral micro or macronodular adrenal hyperplasia.","line_of_therapy":"maintenance","evidence_grade":"1B","guideline_year":null}],"source":"Drug Landscape verified database"}